<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03359889</url>
  </required_header>
  <id_info>
    <org_study_id>1321-0023</org_study_id>
    <nct_id>NCT03359889</nct_id>
  </id_info>
  <brief_title>PraxbindTM India PMS Program</brief_title>
  <official_title>Post Marketing Surveillance Program of Praxbind Use in India.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This program will be initiated after the commercial availability of PraxbindTM in India. It
      will include patients administered with PraxbindTM into the surveillance program after
      commercial availability in 2 years at selected centres approved by the regulatory authority.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 19, 2018</start_date>
  <completion_date type="Actual">January 13, 2020</completion_date>
  <primary_completion_date type="Actual">January 13, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Any suspected Adverse Drug Reactions</measure>
    <time_frame>within 7 days</time_frame>
    <description>with special focus on hypersensitivity and thrombotic event</description>
  </primary_outcome>
  <primary_outcome>
    <measure>fatal Adverse events</measure>
    <time_frame>within 7 days</time_frame>
    <description>with special focus on hypersensitivity and thrombotic event</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>patients who either received PraxbindTM for emergency surgery/urgent procedures or in life-threatening or uncontrolled bleeding</measure>
    <time_frame>at the end of 2 years</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">5</enrollment>
  <condition>Thromboembolism</condition>
  <arm_group>
    <arm_group_label>patients administered with PraxbindTM</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PraxbindTM</intervention_name>
    <description>Drug</description>
    <arm_group_label>patients administered with PraxbindTM</arm_group_label>
    <other_name>PRAXBIND, Praxbind, Prizbind</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients, who receive PraxbindTM prescribed as per the approved label
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Patients treated with Pradaxa (dabigatran etexilate) capsules with requirement of rapid
        reversal of the anticoagulant effects of dabigatran: For emergency surgery/urgent
        procedures (or) In life-threatening or uncontrolled bleeding

        - Written informed consent in accordance with International Conference on Harmonization
        Good Clinical Practice (GCP) guidelines and local legislation and/or regulations

        Exclusion Criteria:

        -Participation in a PraxbindTM clinical trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Mazumdar Shaw Medical centre</name>
      <address>
        <city>Bangalore</city>
        <zip>560099</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia Asia Referral Hospital</name>
      <address>
        <city>Bengaluru</city>
        <zip>560055</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Care Hospital</name>
      <address>
        <city>Hyderabad</city>
        <zip>500034</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Batra Hospital and Medical Research Centre</name>
      <address>
        <city>New Delhi</city>
        <zip>110 062</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>November 28, 2017</study_first_submitted>
  <study_first_submitted_qc>November 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 2, 2017</study_first_posted>
  <last_update_submitted>February 25, 2020</last_update_submitted>
  <last_update_submitted_qc>February 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thromboembolism</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents, except for the following exclusions: 1. studies in products where Boehringer Ingelheim is not the license holder; 2. studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; 3. studies conducted in a single center or targeting rare diseases (because of limitations with anonymization). Requestors can use the following link http://trials.boehringer-ingelheim.com/ to:
find information in order to request access to clinical study data, for listed studies.
request access to clinical study documents that meet criteria, and upon a signed 'Document Sharing Agreement.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

